243 related articles for article (PubMed ID: 1676321)
1. Acceleration of hemopoietic recovery after autologous bone marrow transplantation by low doses of peripheral blood stem cells.
Lopez M; Mortel O; Pouillart P; Zucker JM; Fechtenbaum J; Douay L; Palangie T; Michon J; Salmon D; Gorin NC
Bone Marrow Transplant; 1991 Mar; 7(3):173-81. PubMed ID: 1676321
[TBL] [Abstract][Full Text] [Related]
2. Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts.
Rowley SD; Piantadosi S; Marcellus DC; Jones RJ; Davidson NE; Davis JM; Kennedy J; Wiley JM; Wingard JR; Yeager AM
Bone Marrow Transplant; 1991 Mar; 7(3):183-91. PubMed ID: 2059755
[TBL] [Abstract][Full Text] [Related]
3. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
4. Addition of peripheral blood stem cells collected without mobilization techniques to transplanted autologous bone marrow did not hasten marrow recovery following myeloablative therapy.
Lobo F; Kessinger A; Landmark JD; Smith DM; Weisenburger DD; Wigton RS; Armitage JO
Bone Marrow Transplant; 1991 Nov; 8(5):389-92. PubMed ID: 1685105
[TBL] [Abstract][Full Text] [Related]
5. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants.
To LB; Roberts MM; Haylock DN; Dyson PG; Branford AL; Thorp D; Ho JQ; Dart GW; Horvath N; Davy ML
Bone Marrow Transplant; 1992 Apr; 9(4):277-84. PubMed ID: 1350938
[TBL] [Abstract][Full Text] [Related]
6. Hemopoietic reconstitution after repeated autologous transplantation with mafosfamide-purged marrow.
Beaujean F; Hartmann O; Benhamou E; Lemerle J; Duedari N
Bone Marrow Transplant; 1989 Sep; 4(5):537-41. PubMed ID: 2790332
[TBL] [Abstract][Full Text] [Related]
7. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
8. High dose therapy and autologous bone marrow versus blood cell rescue. South Island Bone Marrow Transplant Unit.
Hill GR; Inder A; Patton WN; Hart DN
N Z Med J; 1996 Feb; 109(1016):45-8. PubMed ID: 8598936
[TBL] [Abstract][Full Text] [Related]
9. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
Albin N; Douay L; Fouillard L; Laporte JP; Isnard F; Lesage S; Ozsahin H; Bardinet D; Najman A; Gorin NC
Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
[TBL] [Abstract][Full Text] [Related]
10. Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.
Rosenfeld CS; Gremba C; Shadduck RK; Zeigler ZR; Nemunaitis J
Exp Hematol; 1994 Mar; 22(3):290-4. PubMed ID: 7509292
[TBL] [Abstract][Full Text] [Related]
11. In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation.
Lopez M; Mary JY; Sainteny F
Exp Hematol; 1993 Feb; 21(2):311-8. PubMed ID: 8425567
[TBL] [Abstract][Full Text] [Related]
12. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
[TBL] [Abstract][Full Text] [Related]
13. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival.
Körbling M; Fliedner TM; Holle R; Magrin S; Baumann M; Holdermann E; Eberhardt K
Bone Marrow Transplant; 1991 May; 7(5):343-9. PubMed ID: 1676924
[TBL] [Abstract][Full Text] [Related]
14. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
[TBL] [Abstract][Full Text] [Related]
15. Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: differences between peripheral blood stem cell and bone marrow recipients.
Bentley SA; Brecher ME; Powell E; Serody JS; Wiley JM; Shea TC
Bone Marrow Transplant; 1997 Mar; 19(6):557-63. PubMed ID: 9085735
[TBL] [Abstract][Full Text] [Related]
16. Prompt haemopoietic reconstitution following hyperthermia purged autologous marrow and peripheral blood stem cell transplantation in acute myeloid leukaemia.
Herrmann RP; O'Reilly J; Meyer BF; Lazzaro G
Bone Marrow Transplant; 1992 Sep; 10(3):293-5. PubMed ID: 1358379
[TBL] [Abstract][Full Text] [Related]
17. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
Kasow KA; Sims-Poston L; Eldridge P; Hale GA
Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
[TBL] [Abstract][Full Text] [Related]
18. [Favorable effect of hematopoietic stem cells isolated from blood on hematologic recovery following high-dosage chemotherapy].
Richel DJ; Baars JW; Wijngaarden MJ; van der Schoot CE; Vlasveld LT; Rodenhuis S
Ned Tijdschr Geneeskd; 1993 Jan; 137(5):245-50. PubMed ID: 7679478
[TBL] [Abstract][Full Text] [Related]
19. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
[TBL] [Abstract][Full Text] [Related]
20. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. I. Effects of in vitro culturing with IL-3 and GM-CSF on human and mouse bone marrow cells purged with mafosfamide (ASTA-Z).
Slavin S; Mumcuoglu M; Landesberg-Weisz A; Kedar E
Bone Marrow Transplant; 1989 Sep; 4(5):459-64. PubMed ID: 2676042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
